Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
AstraZeneca
Dow
Johnson and Johnson
McKinsey

Last Updated: October 6, 2022

Details for Patent: 9,006,387


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 9,006,387
Title:Anti-viral compounds
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Inventor(s): Wagner; Rolf (Antioch, IL), Pratt; John K. (Kenosha, IL), Liu; Dachun (Waukegan, IL), Tufano; Michael D. (Chicago, IL), DeGoey; David A. (Salem, WI), Kati; Warren M. (Gumee, IL), Hutchins; Charles W. (Green Oaks, IL), Donner; Pamela L. (Mundelein, IL), Randolph; John T. (Libertyville, IL), Motter; Christopher E. (Oak Creek, IL), Nelson; Lissa T. (Highland Park, IL), Patel; Sachin V. (Round Lake, IL), Matulenko; Mark A. (Libertyville, IL), Keddy; Ryan G. (Beach Park, IL), Jinkerson; Tammie K. (Pleasant Prairie, WI), Rockway; Todd W. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Hutchinson; Douglas K. (Antioch, IL), Flentge; Charles A. (Salem, WI), Betebenner; David A. (Libertyville, IL), Sarris; Kathy (Mundelein, IL), Woller; Kevin R. (Antioch, IL), Wagaw; Seble H. (Evanston, IL), Califano; Jean C. (Whitefish Bay, WI), Li; Wenke (Gumee, IL), Caspi; Daniel D. (Evanston, IL), Bellizzi; Mary E. (North Chicago, IL), Gao; Yi (Vernon Hills, IL), Krueger; Allan C. (Gumee, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/180,886
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,006,387
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,006,387

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing TREATMENT OF HCV INFECTION USING OMBITASVIR See Plans and Pricing
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing TREATMENT OF HCV INFECTION USING OMBITASVIR See Plans and Pricing
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing TREATMENT OF HCV INFECTION USING OMBITASVIR See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Dow
Harvard Business School
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.